Wei Zhang, Hao Junguo, Yuan Shi, Li Yajuan, Juan Wu, Sha Xianyi, Fang Xiaoling
School of Pharmacy, Fudan University, Shanghai, China.
Int J Pharm. 2009 Jul 6;376(1-2):176-85. doi: 10.1016/j.ijpharm.2009.04.030. Epub 2009 May 3.
The objective of this study was to optimize and characterize a novel polymeric mixed micelle composed of Pluronic P123 and F127 loaded with paclitaxel (PTX). A Doehlert matrix design was utilized to investigate the effect of four variables, namely P123 mass fraction, amount of water, feeding of PTX and hydration temperature on the responses including drug-loading coefficient (DL %), encapsulation ratio (ER %) and the percentage of PTX precipitated from the drug-loaded mixed micelles after 48 h at 37 (PTX precipitated %) for improvement of drug solubilization efficiency and micelle stability. PTX-loaded P123/F127 mixed micelles were prepared by thin-film hydration method. The optimized formulation showed a particle size of about 25 nm with ER %>90%, and a sustained release behavior compared to Taxol. Micelle formation was confirmed by NMR spectroscopy. The mixed micelles had a low CMC of 0.0059% in water. In addition, micelle stability studies implied that introduction of Pluronic F127 (33 wt%) into P123 micelle system significantly increased the stability of PTX-loaded micelles. More importantly, in vitro cytotoxicity was assessed using human lung adenocarcinoma cell lines SPC-A1 and A-549 and was compared to Taxol and the free drug. The cell viability assay against A-549 cells exhibited the 50% inhibition concentration (IC50) of PTX-loaded P123/F127 mixed micelles (0.1 microg/ml) was much lower than those of Taxol injection (0.4 microg/ml) and the free PTX (1.7 microg/ml). Therefore, PTX-loaded P123/F127 mixed micelles may be considered as an effective anticancer drug delivery system for cancer chemotherapy.
本研究的目的是优化并表征一种由普朗尼克P123和F127组成、负载紫杉醇(PTX)的新型聚合物混合胶束。采用Doehlert矩阵设计来研究四个变量,即P123质量分数、水量、PTX投料量和水合温度对包括载药系数(DL%)、包封率(ER%)以及在37℃下48小时后从载药混合胶束中沉淀的PTX百分比(PTX沉淀%)等响应的影响,以提高药物溶解效率和胶束稳定性。通过薄膜水合法制备了负载PTX的P123/F127混合胶束。优化后的制剂粒径约为25 nm,ER%>90%,与紫杉醇相比具有缓释行为。通过核磁共振光谱证实了胶束的形成。该混合胶束在水中的临界胶束浓度(CMC)较低,为0.0059%。此外,胶束稳定性研究表明,将普朗尼克F127(33 wt%)引入P123胶束体系可显著提高负载PTX胶束的稳定性。更重要的是,使用人肺腺癌细胞系SPC-A1和A-549评估了体外细胞毒性,并与紫杉醇和游离药物进行了比较。针对A-549细胞的细胞活力测定显示,负载PTX的P123/F127混合胶束的50%抑制浓度(IC50)(0.1微克/毫升)远低于紫杉醇注射液(0.4微克/毫升)和游离PTX(1.7微克/毫升)。因此,负载PTX的P123/F127混合胶束可被视为一种有效的癌症化疗抗癌药物递送系统。